Source:http://linkedlifedata.com/resource/pubmed/id/12828502
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
9
|
| pubmed:dateCreated |
2003-6-27
|
| pubmed:abstractText |
SLI-381 is an extended-release formulation of short-acting Adderall, a racemic mixture of dextro- and levo-isomers of amphetamine salts. Drug-containing microbeads within the SLI-381 capsule give a double-pulsed delivery, similar to that achieved by two equal doses of the short-acting formulation administered 4 hours apart. In an intent-to-treat analysis of a 3-week, double-blind study in 563 children with attention-deficit hyperactivity disorder (ADHD), SLI-381 10, 20 or 30 mg once daily improved mean morning and afternoon behaviour scores compared with baseline significantly more than placebo (p < 0.001 for all comparisons), as assessed by the Connors Global Index Scale for teachers (CGIS-T). Following treatment, CGIS-T scores were similar to those reported in children without ADHD. In the same study, a dose-response relationship was observed, and increasing the dosage of SLI-381 by 10mg at weekly intervals, to a maximum of 30 mg once daily, resulted in further improvements in the scores of the CGIS-T. After early morning administration of SLI-381 in this double-blind study, late-afternoon scores of the CGIS for parents were similar to morning scores. SLI-381 was generally well tolerated in randomised trials in children with ADHD for up to 24 months. Overall, adverse events were mild to moderate in intensity.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:issn |
1172-7047
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
17
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
669-75; discussion 676-7
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:12828502-Adult,
pubmed-meshheading:12828502-Amphetamines,
pubmed-meshheading:12828502-Attention Deficit Disorder with Hyperactivity,
pubmed-meshheading:12828502-Child,
pubmed-meshheading:12828502-Clinical Trials as Topic,
pubmed-meshheading:12828502-Delayed-Action Preparations,
pubmed-meshheading:12828502-Drug Combinations,
pubmed-meshheading:12828502-Human Experimentation,
pubmed-meshheading:12828502-Humans,
pubmed-meshheading:12828502-Time Factors
|
| pubmed:year |
2003
|
| pubmed:articleTitle |
SLI-381 (Adderall XR).
|
| pubmed:affiliation |
Adis International Limited, Mairangi Bay, Auckland, New Zealand. demail@adis.co.nz
|
| pubmed:publicationType |
Journal Article
|